COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of NGM313 in Obese Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03298464
Recruitment Status : Completed
First Posted : October 2, 2017
Last Update Posted : March 13, 2019
Information provided by (Responsible Party):
NGM Biopharmaceuticals, Inc

Brief Summary:
The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants

Condition or disease Intervention/treatment Phase
Obese Biological: NGM313 Drug: Pioglitazone Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat
Actual Study Start Date : September 11, 2017
Actual Primary Completion Date : June 19, 2018
Actual Study Completion Date : July 17, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NGM313 Biological: NGM313
Subcutaneous injection

Active Comparator: Pioglitazone Drug: Pioglitazone
White to off-white round tablet

Primary Outcome Measures :
  1. Evaluation of whole body insulin sensitivity measured as insulin sensitivity index (M and Si) following intravenous insulin administration [ Time Frame: 28 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body mass index (BMI) of 30-43 kg/m2
  • Waist circumference > 40 inches in males or > 30 inches in females
  • Normal ECG readings

Exclusion Criteria:

  • Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
  • History of any known Congestive heart failure (CHF)
  • History of macrovascular disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03298464

Layout table for location information
United States, California
Chula Vista, California, United States, 91911
Sponsors and Collaborators
NGM Biopharmaceuticals, Inc
Layout table for additonal information
Responsible Party: NGM Biopharmaceuticals, Inc Identifier: NCT03298464    
Other Study ID Numbers: 17-0202
First Posted: October 2, 2017    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Body Weight
Hypoglycemic Agents
Physiological Effects of Drugs